TY - JOUR

T1 - Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe

T2 - The ECCO-EpiCom Cohort

AU - Burisch, Johan

AU - Pedersen, Natalia

AU - Cukovic-Cavka, Silvja

AU - Turk, Niksa

AU - Kaimakliotis, Ioannis

AU - Duricova, Dana

AU - Shonová, Olga

AU - Vind, Ida

AU - Avnstrøm, Søren

AU - Thorsgaard, Niels

AU - Krabbe, Susanne

AU - Andersen, Vibeke

AU - Dahlerup Jens, Frederik

AU - Kjeldsen, Jens

AU - Salupere, Riina

AU - Olsen, Jóngerð

AU - Nielsen, Kári Rubek

AU - Manninen, Pia

AU - Collin, Pekka

AU - Katsanos, Konstantinnos H

AU - Tsianos, Epameinondas V

AU - Ladefoged, Karin

AU - Lakatos, Laszlo

AU - Bailey, Yvonne

AU - O'Morain, Colm

AU - Schwartz, Doron

AU - Odes, Selwyn

AU - Martinato, Matteo

AU - Lombardini, Silvia

AU - Jonaitis, Laimas

AU - Kupcinskas, Limas

AU - Turcan, Svetlana

AU - Barros, Louisa

AU - Magro, Fernando

AU - Lazar, Daniela

AU - Goldis, Adrian

AU - Nikulina, Inna

AU - Belousova, Elena

AU - Fernandez, Alberto

AU - Hernandez, Vicent

AU - Almer, Sven

AU - Zhulina, Yaroslava

AU - Halfvarson, Jonas

AU - Tsai, Her-Hsin

AU - Sebastian, Shaji

AU - Lakatos, Peter Laszlo

AU - Langholz, Ebbe

AU - Munkholm, Pia

AU - EpiCom Group

PY - 2014/1

Y1 - 2014/1

N2 - BACKGROUND: The EpiCom cohort is a prospective, population-based, inception cohort of inflammatory bowel disease (IBD) patients from 31 European centers covering a background population of 10.1 million. The aim of this study was to assess the 1-year outcome in the EpiCom cohort.METHODS: Patients were followed-up every third month during the first 12 (±3) months, and clinical data, demographics, disease activity, medical therapy, surgery, cancers, and deaths were collected and entered in a Web-based database (www.epicom-ecco.eu).RESULTS: In total, 1367 patients were included in the 1-year follow-up. In western Europe, 65 Crohn's disease (CD) (16%), 20 ulcerative colitis (UC) (4%), and 4 IBD unclassified (4%) patients underwent surgery, and in eastern Europe, 12 CD (12%) and 2 UC (1%) patients underwent surgery. Eighty-one CD (20%), 80 UC (14%), and 13 (9%) IBD unclassified patients were hospitalized in western Europe compared with 17 CD (16%) and 12 UC (8%) patients in eastern Europe. The cumulative probability of receiving immunomodulators was 57% for CD in western (median time to treatment 2 months) and 44% (1 month) in eastern Europe, and 21% (5 months) and 5% (6 months) for biological therapy, respectively. For UC patients, the cumulative probability was 22% (4 months) and 15% (3 months) for immunomodulators and 6% (3 months) and 1% (12 months) for biological therapy, respectively in the western and eastern Europe.DISCUSSION: In this cohort, immunological therapy was initiated within the first months of disease. Surgery and hospitalization rates did not differ between patients from eastern and western Europe, although more western European patients received biological agents and were comparable to previous population-based inception cohorts.

AB - BACKGROUND: The EpiCom cohort is a prospective, population-based, inception cohort of inflammatory bowel disease (IBD) patients from 31 European centers covering a background population of 10.1 million. The aim of this study was to assess the 1-year outcome in the EpiCom cohort.METHODS: Patients were followed-up every third month during the first 12 (±3) months, and clinical data, demographics, disease activity, medical therapy, surgery, cancers, and deaths were collected and entered in a Web-based database (www.epicom-ecco.eu).RESULTS: In total, 1367 patients were included in the 1-year follow-up. In western Europe, 65 Crohn's disease (CD) (16%), 20 ulcerative colitis (UC) (4%), and 4 IBD unclassified (4%) patients underwent surgery, and in eastern Europe, 12 CD (12%) and 2 UC (1%) patients underwent surgery. Eighty-one CD (20%), 80 UC (14%), and 13 (9%) IBD unclassified patients were hospitalized in western Europe compared with 17 CD (16%) and 12 UC (8%) patients in eastern Europe. The cumulative probability of receiving immunomodulators was 57% for CD in western (median time to treatment 2 months) and 44% (1 month) in eastern Europe, and 21% (5 months) and 5% (6 months) for biological therapy, respectively. For UC patients, the cumulative probability was 22% (4 months) and 15% (3 months) for immunomodulators and 6% (3 months) and 1% (12 months) for biological therapy, respectively in the western and eastern Europe.DISCUSSION: In this cohort, immunological therapy was initiated within the first months of disease. Surgery and hospitalization rates did not differ between patients from eastern and western Europe, although more western European patients received biological agents and were comparable to previous population-based inception cohorts.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Combined Modality Therapy

KW - Databases, Factual

KW - Disease Progression

KW - Europe

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Incidence

KW - Inflammatory Bowel Diseases

KW - Male

KW - Middle Aged

KW - Prognosis

KW - Prospective Studies

KW - Remission Induction

KW - Young Adult

U2 - 10.1097/01.MIB.0000436277.13917.c4

DO - 10.1097/01.MIB.0000436277.13917.c4

M3 - Journal article

C2 - 24252978

VL - 20

SP - 36

EP - 46

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 1

ER -